SIETES :: 91969 citas

Resultados de la búsqueda por RALES REFINAR BÚSQUEDA

1.

Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]

2.

Anónimo. Spironolactone - potion or poison?. Drug Ther Bull 2017;55:13. [Ref.ID 101402]

3.

Hu L-j, Chen Y-q, Deng S-b, Du J-l, She Q. Additional use of an aldosterone antagonist in patients with mild to moderate chronic heart failure: a systematic review and meta-analysis. Br J Clin Pharmacol 2013;75:1202-12. [Ref.ID 95327]

4.

Krum H, Teerlink JR. Heart failure 2. Medical therapy for chronic heart failure. Lancet 2011;378:713-21. [Ref.ID 91440]

5.

Zannad F, McMurray JJV, Swedberg K. Eplerenone in mild heart failure. Author/editor response. N Engl J Med 2011;364:1372. [Ref.ID 90543]

6.

Dastidar AG. Eplerenone in mild heart failure. N Engl J Med 2011;364:1371. [Ref.ID 90542]

7.

Tomaschitz A, Marz W. Eplerenone in mild heart failure. N Engl J Med 2011;364:1371. [Ref.ID 90541]

8.

Gus M, Fuchs FD. Eplerenone in mild heart failure. N Engl J Med 2011;364:1370. [Ref.ID 90540]

9.

Pascual-Figal DA, Sanchez-Mas J, Januzzi JL. Eplerenone in mild heart failure. N Engl J Med 2011;364:1370. [Ref.ID 90539]

10.

Armstrong PW. Aldosterone antagonists - Last man standing?. N Engl J Med 2011;364:79-81. [Ref.ID 90016]

11.

Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, for the EMPHASIS-HF Study group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21. [Ref.ID 90013]

12.

Wei L, Struthers AD, Fahey T, Watson AD, MacDonald TM. Spironolactone use and renal toxicity: population based longitudinal analysis. BMJ 2010;340:1233. [Ref.ID 88639]

13.

Krum H, Abraham WT. Heart failure. Lancet 2009;373:941-55. [Ref.ID 85474]

14.

Hauben M, Reich L, Gerrits CM, Madigan D. Detection of spironolactone-associated hyperkalaemia following the Randomized Aldactone Evaluation Study (RALES). Drug Saf 2007;30:1143-9. [Ref.ID 81828]

15.

Galve E. Fármacos antialdosterónicos: su papel en la insuficiencia cardíaca. Med Clin (Barc) 2008;130:30-4. [Ref.ID 81627]

16.

Hauben M, Reich L, Gerrits CM. Reports of hyperkalemia after publication of RALES - a pharmacovigilance study. Pharmacoepidemiol Drug Saf 2006;15:775-83. [Ref.ID 78689]

17.

McMurray JJV, Pfeffer MA. Heart failure. Lancet 2005;365:1877-89. [Ref.ID 73990]

18.

Lechat PH. Essais cliniques des traitements ß-bloquants dans l'insuffisance cardiaque: historie, synthèse et perspectives. Therapie 2004;59:517-26. [Ref.ID 72214]

19.

Anónimo. Spironolactone and ACE inhibitors: link to hyperkalaemia. WHO Drug Information 2004;18:206-7. [Ref.ID 71949]

20.

Wang K. "Pseudoinfarction" pattern due to hyperkalemia. N Engl J Med 2004;351:593. [Ref.ID 71066]